摘要
目的探讨乳腺癌中CD44v6、整合素α5β1的表达及其与预后的关系。方法应用免疫组化S-P法,检测80例乳腺癌中CD44v6和整合素α5β1表达,分析其与临床病理学特征的关系。结果80例乳腺癌中CD44v6、整合素α5β1表达阳性率分别为60.0%(48/80)和100%。CD44v6蛋白阳性表达率与肿瘤大小及淋巴结转移呈正相关(P<0.05),与预后呈负相关(P<0.01);整合素α5β1阳性表达率与组织学分级及淋巴结转移呈负相关(P<0.05),与预后呈正相关(P<0.05)。结论CD44v6、整合素α5β1的表达与乳腺癌的进展和转移密切相关,术后对乳腺癌组织CD44v6、整合素α5β1进行常规检测,有助于更准确评估乳腺癌的生物学行为,指导术后辅助治疗。
Objective To study the relationship between the expression of CD44v6 and integrin alpha 5betal and prognosis in breast cancer. Methods S-P immunohistoehemieal method was used to examine the expression of CD44v6 and integrin α5β1 in 80 cases of breast cancer and its relationship with elinieopathological characteristics was analyzed. Results The positive rates of CD44v6 and integrin α5β1 were 60.0% （48/80）and 100.0% respectively. The expression of CD44v6 was positively correlated with tumor size and lymph node metastasis（ P 〈 0.05 ）and was negatively correlated with prognosis（ P 〈 0.05 ）. The expression of integrin α5β1 was negatively correlated with histological grade and lymph node metastasis（ P 〈 0.05） and was positively correlated with prognosis （P 〈 0.05）. Conclusions The expression of CD44v6 and integrin α5β1 is closely correlated with the development and metastasis of breast cancer. The expression of CD44v6 and integrin α5β1 is routinely examined,which helps to evaluate the behavior of breast cancer and instruct the appropriate postoperative adjuvant therapy.
出处
《中国肿瘤临床与康复》
2006年第5期391-393,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
山东省教育厅科技发展计划项目(j02k14)
